GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Mutant KRas is a significant driver of human oncogenesis and confers resistance to therapy, underscoring the need to develop approaches that disable mutant KRas-driven tumors. Because targeting KRas directly has proven difficult, identifying vulnerabilities specific for mutant KRas tumors is an impo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Kazi, Aslamuzzaman, Xiang, Shengyan, Yang, Hua, Delitto, Daniel, Trevino, José, Jiang, Rays H. Y., Ayaz, Muhammad, Lawrence, Harshani R., Kennedy, Perry, Sebti, Saïd M.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279809/
https://ncbi.nlm.nih.gov/pubmed/30514931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07644-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados